Price: $14.88
· 1 day: -4.71% · 5 days: +15.53% · 1 month: -42.15% · YTD: -35.30%
As of 2026-09-23 20:00 UTC.
52-week range: $12.73 – $39.89 (currently at 8% of the range).
The read
RARE is in a downtrend, momentum firm. $15 is the level overhead; $14 the first support below.
4 of 6 technical checks lean bearish.
Price vs 50-day: below
Price vs 200-day: below
50d vs 200d avg: below
MACD: bullish
RSI momentum: 18
5-day tape: +15.5%
Trend
Downtrend · below 50-day & below 200-day
Momentum
RSI 17.99 · neutral · MACD bullish
Trend strength
ADX 32.2 · strong trend
Location
-35.8% vs 50-day MA
52-week range
-59% from high · +16% from low
Volatility
ATR 1.77 · ~11.9%/day
Key levels
Level
Type
Distance
$15.0 (resistance)
round
0.81%
$16.0 (resistance)
round
7.53%
$23.17 (resistance)
sma 50
55.71%
$14.0 (support)
round
-5.91%
$13.0 (support)
round
-12.63%
$12.88 (support)
52w low
-13.44%
Indicators
RSI (14)
17.99
MACD
-2.8858
ADX (14)
32.2
ATR (14)
1.77
50-day average
$23.17
200-day average
$24.83
Next earnings: 2026-11-03.
Latest RARE news
Ultragenyx Pharmaceutical Inc. — Form 8-K: 8.01 Other Events — Ultragenyx Pharmaceutical Inc. filed a Form 8-K with the SEC on September 17, 2026, disclosing an item under Section 8.01 (Other Events). The filing, sourced from SEC EDGAR, does not specify the nature of the event or pr (SEC EDGAR, 2026-09-17)
Ultragenyx Pharmaceutical Inc. — Form 8-K: 8.01 Other Events — Ultragenyx Pharmaceutical Inc. filed a Form 8-K with the SEC on September 2, 2026, disclosing an event under Item 8.01 (Other Events). The filing does not specify the nature of the event, and no financial details or oper (SEC EDGAR, 2026-09-02)
Ultragenyx Pharmaceutical Inc. — Form 8-K: 8.01 Other Events — Ultragenyx Pharmaceutical Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 19, 2026. The filing was made under Item 8.01, which covers other events, and was submitted through the SEC's EDG (SEC EDGAR, 2026-08-19)
Ultragenyx Pharmaceutical Inc. — Form 8-K: 8.01 Other Events — Ultragenyx Pharmaceutical Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 11, 2026. The filing was made under Item 8.01, designated as "Other Events." The disclosure did not include speci (SEC EDGAR, 2026-08-11)
Ultragenyx Pharmaceutical Inc. — Quarterly report (10-Q) — Ultragenyx Pharmaceutical Inc. filed its Form 10-Q quarterly report with the SEC on August 5, 2026, for the period ended June 30, 2026. The company reported second-quarter fiscal 2026 revenue of $214.0 million, up 29% ye (SEC EDGAR, 2026-08-04)
(BBIO.O) | Stock Price & Latest News — Intellia Therapeutics has temporarily halted dosing and patient screening in two late-stage gene therapy studies after a participant experienced serious liver injury. The company disclosed the development on Monday, caus (Reuters, 2026-07-31)
Betting on Drug Trials and Approvals Prompts Concerns About Undermining Research — Prediction markets Kalshi and Polymarket have introduced wagering on FDA drug approvals and clinical trial outcomes, including bets on cancer treatments such as camizestrant, which traders priced at a 64 percent approval (The New York Times, 2026-07-30)